SG11201400222RA - Caninised tumour necrosis factor antibodies and methods of using the same - Google Patents
Caninised tumour necrosis factor antibodies and methods of using the sameInfo
- Publication number
- SG11201400222RA SG11201400222RA SG11201400222RA SG11201400222RA SG11201400222RA SG 11201400222R A SG11201400222R A SG 11201400222RA SG 11201400222R A SG11201400222R A SG 11201400222RA SG 11201400222R A SG11201400222R A SG 11201400222RA SG 11201400222R A SG11201400222R A SG 11201400222RA
- Authority
- SG
- Singapore
- Prior art keywords
- caninised
- methods
- same
- necrosis factor
- tumour necrosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161529020P | 2011-08-30 | 2011-08-30 | |
US201161531439P | 2011-09-06 | 2011-09-06 | |
PCT/GB2012/052115 WO2013030568A1 (en) | 2011-08-30 | 2012-08-29 | Caninised tumour necrosis factor antibodies and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201400222RA true SG11201400222RA (en) | 2014-03-28 |
Family
ID=47755387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201400222RA SG11201400222RA (en) | 2011-08-30 | 2012-08-29 | Caninised tumour necrosis factor antibodies and methods of using the same |
Country Status (10)
Country | Link |
---|---|
US (1) | US20140294815A1 (en) |
EP (1) | EP2751139A1 (en) |
JP (1) | JP2014526902A (en) |
KR (1) | KR20140063752A (en) |
CN (1) | CN103958545A (en) |
AU (1) | AU2012300632A1 (en) |
CA (1) | CA2847020A1 (en) |
HK (1) | HK1199735A1 (en) |
SG (1) | SG11201400222RA (en) |
WO (1) | WO2013030568A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014368453B2 (en) | 2013-12-20 | 2020-04-16 | Intervet International B.V. | Caninized murine anti-canine PD-1 antibodies |
BR112017006203A2 (en) | 2014-09-30 | 2018-05-02 | Intervet International B.V. | isolated, caninized and monoclonal antibodies or antigen binding fragment thereof, isolated nucleic acid, expression vector, host cell, isolated antigenic peptide, fusion protein, pharmaceutical composition, and method of enhancing the activity of an immune cell. |
US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
CN107375950B (en) * | 2017-08-02 | 2020-10-09 | 深圳大学 | Recombinant Gal-1 allergic environment immune tolerance induction model and establishment method |
WO2022133325A2 (en) * | 2020-12-18 | 2022-06-23 | Kindred Biosciences, Inc. | Tnf alpha and ngf antibodies for veterinary use |
TWI821881B (en) * | 2021-01-29 | 2023-11-11 | 醫研生物科技有限公司 | Tumor necrosis factor alpha recombinant antibody and use thereof |
CN117343185B (en) * | 2023-12-06 | 2024-03-01 | 北京伟杰信生物科技有限公司 | Anti-canine PD-1 antibody and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
DE68913658T3 (en) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Cloning of immunoglobulin sequences from the variable domains |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
AU640397B2 (en) | 1989-08-25 | 1993-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin |
CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
EP2331579B1 (en) * | 2008-09-04 | 2017-07-05 | Vet Therapeutics, Inc. | Monoclonal antibodies |
-
2012
- 2012-08-29 EP EP12761783.5A patent/EP2751139A1/en not_active Withdrawn
- 2012-08-29 AU AU2012300632A patent/AU2012300632A1/en not_active Abandoned
- 2012-08-29 KR KR1020147008446A patent/KR20140063752A/en not_active Application Discontinuation
- 2012-08-29 WO PCT/GB2012/052115 patent/WO2013030568A1/en active Application Filing
- 2012-08-29 JP JP2014527733A patent/JP2014526902A/en active Pending
- 2012-08-29 US US14/241,616 patent/US20140294815A1/en not_active Abandoned
- 2012-08-29 CA CA2847020A patent/CA2847020A1/en not_active Abandoned
- 2012-08-29 CN CN201280052125.8A patent/CN103958545A/en active Pending
- 2012-08-29 SG SG11201400222RA patent/SG11201400222RA/en unknown
-
2015
- 2015-01-07 HK HK15100122.4A patent/HK1199735A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ621619A (en) | 2015-03-27 |
WO2013030568A1 (en) | 2013-03-07 |
AU2012300632A1 (en) | 2014-03-13 |
HK1199735A1 (en) | 2015-07-17 |
US20140294815A1 (en) | 2014-10-02 |
CA2847020A1 (en) | 2013-03-07 |
JP2014526902A (en) | 2014-10-09 |
KR20140063752A (en) | 2014-05-27 |
EP2751139A1 (en) | 2014-07-09 |
CN103958545A (en) | 2014-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1255608A1 (en) | Anti-htra1 antibodies and methods of use | |
IL250691B (en) | Anti-ox40 antibodies and methods of using the same | |
HK1213581A1 (en) | Anti-cd40 antibodies and methods of use -cd40 | |
EP2748199A4 (en) | Anti-ox40 antibodies and methods of using the same | |
ZA201308022B (en) | Anti-cd40 antibodies and methods of use | |
GB201114858D0 (en) | Anti-nerve growth factor antibodies and methods of using the same | |
FI3556774T3 (en) | Anti-cd40 antibodies and uses thereof | |
HK1201843A1 (en) | Anti-polyubiquitin antibodies and methods of use | |
ZA201403760B (en) | Anti-cd98 antibodies and methods of use thereof | |
GB201517547D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
EP2611832A4 (en) | Anti-cxcl13 antibodies and methods of using the same | |
HK1199735A1 (en) | Caninised tumour necrosis factor antibodies and methods of using the same | |
HK1201541A1 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
EP2682405A4 (en) | Tumor necrosis factor- humanized antibody | |
GB201519606D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same |